Ad Header



The Pulse of the Pharmaceutical Industry

FDA clears nerve stimulator for opioid withdrawal symptoms

Written by: | | Dated: Wednesday, November 15th, 2017


(Reuters) – The U.S. Food and Drug Administration on Wednesday cleared for use an electrical nerve stimulator designed to reduce the symptoms of opioid withdrawal.

The device, made by privately held Innovative Health Solutions Inc., is placed behind the patient’s ear for up to five days during the acute withdrawal phase.

The FDA authorized the device, known as NSS-2 Bridge, after 73 patients experiencing opioid withdrawal saw a reduction of at least 31 percent in their symptoms.

Symptoms of withdrawal include sweating, tremors, sweating, stomach upset, joint pain and anxiety.


Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation